CADONI, Enzo, Petr VAŇHARA, Elisa VALLETTA, Elisabetta PINNA, Sarah VASCELLARI, Graziano CADDEO, Francesco ISAIA, Alessandra PANI, Josef HAVEL a Tiziana PIVETTA. Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells. Rapid Communications in Mass Spectrometry. HOBOKEN: Wiley InterScience, roč. 33, č. 1, s. 97-106. ISSN 0951-4198. doi:10.1002/rcm.8320. 2019.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells
Autoři CADONI, Enzo (380 Itálie), Petr VAŇHARA (203 Česká republika, domácí), Elisa VALLETTA (380 Itálie), Elisabetta PINNA (380 Itálie), Sarah VASCELLARI (380 Itálie), Graziano CADDEO (380 Itálie), Francesco ISAIA (380 Itálie), Alessandra PANI (380 Itálie), Josef HAVEL (203 Česká republika, domácí) a Tiziana PIVETTA (garant).
Vydání Rapid Communications in Mass Spectrometry, HOBOKEN, Wiley InterScience, 2019, 0951-4198.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 10608 Biochemistry and molecular biology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.200
Kód RIV RIV/00216224:14110/19:00110884
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1002/rcm.8320
UT WoS 000453713000012
Klíčová slova anglicky Mass spectrometric discrimination; phospholipid patterns; cancer cells
Štítky 14110517, podil, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Marie Šípková, DiS., učo 437722. Změněno: 1. 4. 2020 20:58.
Anotace
Rationale Development of therapy-resistant cancer is a major problem in clinical oncology, and there is an urgent need for novel markers identifying development of the resistant phenotype. Lipidomics represents a promising approach to discriminate lipid profiles of malignant phenotype cells. Alterations in phospholipid distribution or chemical composition have been reported in various pathologies including cancer. Here we were curious whether quantitative differences in phospholipid composition between cisplatin-resistant and -sensitive model cancer cell lines could be revealed by mass spectrometric means. Methods The phospholipid contents of cell membranes of the cancer cell lines CCRF-CEM and A2780, both responsive and resistant to cisplatin, were analyzed by solid-phase extraction (SPE) and electrospray ionization mass spectrometry (ESI-MS and tandem mass spectrometry (MS/MS)). Extracts were obtained by disruption of cells with a dounce tissue grinder set followed by centrifugation. To minimize the enzymatic activity, phospholipids were extracted from cell extracts by SPE immediately after the cell lysis and analyzed by MS. Both supernatant and pellet fractions of cell extracts were analyzed. Results A phospholipid profile specific for cell lines and their phenotypes was revealed. We have documented by quantitative analysis that phosphocholines PC P-34:0, PC 34:1, PC 20:2_16:0, LPC 18:1 and LPC 16:0 PLs were present in the 200-400 mu M concentration range in CCRF-CEM cisplatin-responsive cells, but absent in their cisplatin-resistant cells. Similarly, PC 34:1, LPC 18:1 and LPC 16:0 were increased in cisplatin-responsive A2780 cells, and PC 20:2_16:0 was downregulated in cisplatin-resistant A2780 cells. Conclusions In this work we showed that the ESI-MS analysis of the lipid content of the therapy-resistant and -sensitive cells can clearly distinguish the phenotypic pattern and determine the potential tumor response to cytotoxic therapy. Lipid entities revealed by mass spectrometry and associated with development of therapy resistance can thus support molecular diagnosis and provide a potential complementary cancer biomarker.
VytisknoutZobrazeno: 19. 4. 2024 23:08